Advertisement
Advertisement
APRE
Aprea Therapeutics, Inc. Common stock
0.52
USDSponsored
+0.02
+4.50%
Nov 06, 15:59 UTC -5
Closed
Pre-Market
0.54
+0.02
+3.36%
Aprea Therapeutics, Inc. Common stock (APRE) Earnings
APRE Earnings Reports
Positive Surprise Ratio
APRE beat 19 of 28 last estimates.
68%
Next Report
Date of Next Report
Mar 15, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q3 26 (Revenue/ EPS)
--
/-11.11%
Implied change from Q4 25 (Revenue/ EPS)
-100.00%
/-75.00%
Aprea Therapeutics, Inc. Common stock earnings per share and revenue
On Nov 04, 2026, APRE reported earnings of -0.09 USD per share (EPS) for Q3 26, missing the estimate of -0.07 USD, resulting in a -17.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.90% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an decrease of -11.11% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
Medicus Pharma Ltd. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$6.75
Actual
-$11.64
Surprise
-72.25%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
FAQ
What were Aprea Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Aprea Therapeutics, Inc. Common stock reported EPS of -$0.09, missing estimates by -17.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Aprea Therapeutics, Inc. Common stock's Q3 2026 earnings?
The stock price moved down -1.9%, changed from $0.52 before the earnings release to $0.51 the day after.
When is Aprea Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for Mar 15, 2027.
What are the forecasts for Aprea Therapeutics, Inc. Common stock's next earnings report?
Based on --
analysts, Aprea Therapeutics, Inc. Common stock is expected to report EPS of -$0.08 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.